At the pulse of heart disease
We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.
Mode of Action
The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.
CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.
News
TIDES Europe: Oligonucleotide & Peptide Therapeutics
Event ·
November 13–13, 2024
· Hamburg, Germany
DIA/FDA Oligonucleotide-Based Therapeutics Conference
Event ·
October 28–30, 2024
· Washington DC, USA
International Society for Heart Research SEA 2024 Meeting
Event ·
October 1–4, 2024
· Singapore
